Role of the YAP oncoprotein in priming ras-driven rhabdomyosarcoma

PLoS ONE

Volumn 10, Issue 10, 2015, Pages

  Slemmons, Katherine K ^a   Crose, Lisa E S ^a   Rudzinski, Erin ^b   Bentley, Rex C ^a   Linardic, Corinne M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b SEATTLE CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CONNECTIVE TISSUE GROWTH FACTOR; ONCOPROTEIN; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; VERTEPORFIN; YAP ONCOPROTEIN; PHOSPHOPROTEIN; RAS PROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TELOMERASE; YAP PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CARCINOGENESIS; CELL DIFFERENTIATION; CONTROLLED STUDY; CTGF GENE; DISEASE ASSOCIATION; EMBRYONAL RHABDOMYOSARCOMA; GAIN OF FUNCTION MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; ONCOGENE RAS; PHENOTYPE; PLEOMORPHIC RHABDOMYOSARCOMA; POINT MUTATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RHABDOMYOSARCOMA; RHABDOMYOSARCOMA CELL LINE; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; ANIMAL; CELL PROLIFERATION; CELL SURVIVAL; GENETICS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; METABOLISM; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; SCID MOUSE; TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MICE; MICE, SCID; PHOSPHOPROTEINS; RAS PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; RHABDOMYOSARCOMA; TELOMERASE;

EID: 84949685888     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0140781     Document Type: Article

References (56)

1. Ognjanovic S, Linabery AM, Charbonneau B, Ross JA. Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975-2005. Cancer. 2009; 115(18):4218-26. doi: 10.1002/ cncr.24465 PMID: 19536876
2. Egas-Bejar D, Huh WW. Rhabdomyosarcoma in adolescent and young adult patients: current perspectives. Adolescent health, medicine and therapeutics. 2014; 5:115-25. doi: 10.2147/AHMT.S44582 PMID: 24966711
3. Perkins SM, Shinohara ET, DeWees T, Frangoul H. Outcome for children with metastatic solid tumors over the last four decades. PLoS One. 2014; 9(7):e100396. doi: 10.1371/journal.pone.0100396 PMID: 25003594
4. Stratton MR, Fisher C, Gusterson BA, Cooper CS. Detection of point mutations in N-ras and K-ras genes of human embryonal rhabdomyosarcomas using oligonucleotide probes and the polymerase chain reaction. Cancer research. 1989; 49(22):6324-7. PMID: 2680062
5. Wilke W, Maillet M, Robinson R. H-ras-1 point mutations in soft tissue sarcomas. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc. 1993; 6(2):129-32.
6. Chen Y, Takita J, Hiwatari M, Igarashi T, Hanada R, Kikuchi A, et al. Mutations of the PTPN11 and RAS genes in rhabdomyosarcoma and pediatric hematological malignancies. Genes, chromosomes & cancer. 2006; 45(6):583-91. PMID: 16518851
7. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA. Creation of human tumour cells with defined genetic elements. Nature. 1999; 400(6743):464-8. PMID: 10440377
8. Linardic CM, Downie DL, Qualman S, Bentley RC, Counter CM. Genetic modeling of human rhabdomyosarcoma. Cancer research. 2005; 65(11):4490-5. PMID: 15930263
9. Blum JM, Ano L, Li Z, Van Mater D, Bennett BD, Sachdeva M, et al. Distinct and overlapping sarcoma subtypes initiated from muscle stem and progenitor cells. Cell reports. 2013; 5(4):933-40. doi: 10.1016/ j.celrep.2013.10.020 PMID: 24239359
10. Langenau DM, Keefe MD, Storer NY, Guyon JR, Kutok JL, Le X, et al. Effects of RAS on the genesis of embryonal rhabdomyosarcoma. Genes & development. 2007; 21(11):1382-95. PMID: 17510286
11. Hettmer S, Liu J, Miller CM, Lindsay MC, Sparks CA, Guertin DA, et al. Sarcomas induced in discrete subsets of prospectively isolated skeletal muscle cells. Proceedings of the National Academy of Sciences of the United States of America. 2011; 108(50):20002-7. doi: 10.1073/pnas.1111733108 PMID: 22135462
12. Tsumura H, Yoshida T, Saito H, Imanaka-Yoshida K, Suzuki N. Cooperation of oncogenic K-ras and p53 deficiency in pleomorphic rhabdomyosarcoma development in adult mice. Oncogene. 2006; 25 (59):7673-9. PMID: 16785989
13. Chen X, Stewart E, Shelat AA, Qu C, Bahrami A, Hatley M, et al. Targeting oxidative stress in embryonal rhabdomyosarcoma. Cancer cell. 2013; 24(6):710-24. doi: 10.1016/j.ccr.2013.11.002 PMID: 24332040
14. Shern JF, Chen L, Chmielecki J, Wei JS, Patidar R, Rosenberg M, et al. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer discovery. 2014; 4(2):216-31. doi: 10.1158/2159-8290.CD-13-0639 PMID: 24436047
15. Zhao B, Tumaneng K, Guan KL. The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal. Nature cell biology. 2011; 13(8):877-83. doi: 10.1038/ncb2303 PMID: 21808241
16. Harvey KF, Zhang X, Thomas DM. The Hippo pathway and human cancer. Nature reviews Cancer. 2013; 13(4):246-57. doi: 10.1038/nrc3458 PMID: 23467301
17. Tremblay AM, Missiaglia E, Galli GG, Hettmer S, Urcia R, Carrara M, et al. The Hippo transducer YAP1 transforms activated satellite cells and is a potent effector of embryonal rhabdomyosarcoma formation. Cancer cell. 2014; 26(2):273-87. doi: 10.1016/j.ccr.2014.05.029 PMID: 25087979
18. Helias-Rodzewicz Z, Perot G, Chibon F, Ferreira C, Lagarde P, Terrier P, et al. YAP1 and VGLL3, encoding two cofactors of TEAD transcription factors, are amplified and overexpressed in a subset of soft tissue sarcomas. Genes, chromosomes & cancer. 2010; 49(12):1161-71. doi: 10.1002/gcc.20825 PMID: 20842732
19. Crose LE, Galindo KA, Kephart JG, Chen C, Fitamant J, Bardeesy N, et al. Alveolar rhabdomyosarcoma-associated PAX3-FOXO1 promotes tumorigenesis via Hippo pathway suppression. The Journal of clinical investigation. 2014; 124(1):285-96. doi: 10.1172/JCI67087 PMID: 24334454
20. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. doi: 10.1016/j.cell.2011.02.013 PMID: 21376230
21. McAllister RM, Melnyk J, Finkelstein JZ, Adams EC Jr., Gardner MB. Cultivation in vitro of cells derived from a human rhabdomyosarcoma. Cancer. 1969; 24(3):520-6. PMID: 4241949
22. Whang-Peng J, Knutsen T, Theil K, Horowitz ME, Triche T. Cytogenetic studies in subgroups of rhabdomyosarcoma. Genes, chromosomes & cancer. 1992; 5(4):299-310. PMID: 1283318
23. Naini S, Etheridge KT, Adam SJ, Qualman SJ, Bentley RC, Counter CM, et al. Defining the cooperative genetic changes that temporally drive alveolar rhabdomyosarcoma. Cancer research. 2008; 68 (23):9583-8. doi: 10.1158/0008-5472.CAN-07-6178 PMID: 19047133
24. Hinson AR, Jones R, Crose LE, Belyea BC, Barr FG, Linardic CM. Human rhabdomyosarcoma cell lines for rhabdomyosarcoma research: utility and pitfalls. Frontiers in oncology. 2013; 3:183. doi: 10. 3389/fonc.2013.00183 PMID: 23882450
25. Schaaf G, Hamdi M, Zwijnenburg D, Lakeman A, Geerts D, Versteeg R, et al. Silencing of SPRY1 triggers complete regression of rhabdomyosarcoma tumors carrying a mutated RAS gene. Cancer research. 2010; 70(2):762-71. doi: 10.1158/0008-5472.CAN-09-2532 PMID: 20068162
26. Shukla N, Ameur N, Yilmaz I, Nafa K, Lau CY, Marchetti A, et al. Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways. Clinical cancer research: an official journal of the American Association for Cancer Research. 2012; 18(3):748-57.
27. Zhang J, Smolen GA, Haber DA. Negative regulation of YAP by LATS1 underscores evolutionary conservation of the Drosophila Hippo pathway. Cancer research. 2008; 68(8):2789-94. doi: 10.1158/0008-5472.CAN-07-6205 PMID: 18413746
28. Xia Y, Zhang YL, Yu C, Chang T, Fan HY. YAP/TEAD co-activator regulated pluripotency and chemoresistance in ovarian cancer initiated cells. PLoS One. 2014; 9(11):e109575. doi: 10.1371/journal. pone.0109575 PMID: 25369529
29. Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes & development. 2007; 21 (21):2747-61. PMID: 17974916
30. Overholtzer M, Zhang J, Smolen GA, Muir B, Li W, Sgroi DC, et al. Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proceedings of the National Academy of Sciences of the United States of America. 2006; 103(33):12405-10. PMID: 16894141
31. Belyea BC, Naini S, Bentley RC, Linardic CM. Inhibition of the Notch-Hey1 axis blocks embryonal rhabdomyosarcoma tumorigenesis. Clinical cancer research: an official journal of the American Association for Cancer Research. 2011; 17(23):7324-36.
32. Linardic CM, Naini S, Herndon JE 2nd, Kesserwan C, Qualman SJ, Counter CM. The PAX3-FKHR fusion gene of rhabdomyosarcoma cooperates with loss of p16INK4A to promote bypass of cellular senescence. Cancer research. 2007; 67(14):6691-9. PMID: 17638879
33. Kim KH, Park GT, Lim YB, Rue SW, Jung JC, Sonn JK, et al. Expression of connective tissue growth factor, a biomarker in senescence of human diploid fibroblasts, is up-regulated by a transforming growth factor-beta-mediated signaling pathway. Biochemical and biophysical research communications. 2004; 318(4):819-25. PMID: 15147944
34. Moroishi T, Park HW, Qin B, Chen Q, Meng Z, Plouffe SW, et al. A YAP/TAZ-induced feedback mechanism regulates Hippo pathway homeostasis. Genes & development. 2015; 29(12):1271-84. doi: 10. 1101/gad.262816.115 PMID: 26109050
35. Liu-Chittenden Y, Huang B, Shim JS, Chen Q, Lee SJ, Anders RA, et al. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes & development. 2012; 26(12):1300-5. doi: 10.1101/gad.192856.112 PMID: 22677547
36. Song S, Honjo S, Jin J, Chang SS, Scott AW, Chen Q, et al. The Hippo Coactivator YAP1 Mediates EGFR Overexpression and Confers Chemoresistance in Esophageal Cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2015; 21(11):2580-90.
37. Ciamporcero E, Shen H, Ramakrishnan S, Yu Ku S, Chintala S, Shen L, et al. YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage. Oncogene. 2015. doi: 10.1038/onc. 2015.219 PMID: 26119935
38. Yu FX, Luo J, Mo JS, Liu G, Kim YC, Meng Z, et al. Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP. Cancer cell. 2014; 25(6):822-30. doi: 10.1016/j.ccr.2014.04.017 PMID: 24882516
39. Brodowska K, Al-Moujahed A, Marmalidou A, Meyer Zu Horste M, Cichy J, Miller JW, et al. The clinically used photosensitizer Verteporfin (VP) inhibits YAP-TEAD and human retinoblastoma cell growth in vitro without light activation. Experimental eye research. 2014; 124:67-73. doi: 10.1016/j.exer.2014. 04.011 PMID: 24837142
40. Keller C, Guttridge DC. Mechanisms of impaired differentiation in rhabdomyosarcoma. The FEBS journal. 2013; 280(17):4323-34. doi: 10.1111/febs.12421 PMID: 23822136
41. Judson RN, Tremblay AM, Knopp P, White RB, Urcia R, De Bari C, et al. The Hippo pathway member Yap plays a key role in influencing fate decisions in muscle satellite cells. Journal of cell science. 2012; 125(Pt 24):6009-19. doi: 10.1242/jcs.109546 PMID: 23038772
42. Watt KI, Judson R, Medlow P, Reid K, Kurth TB, Burniston JG, et al. Yap is a novel regulator of C2C12 myogenesis. Biochemical and biophysical research communications. 2010; 393(4):619-24. doi: 10. 1016/j.bbrc.2010.02.034 PMID: 20153295
43. Yu L, Wang J. [Clinicopathologic features of pleomorphic rhabdomyosarcoma]. Zhonghua bing li xue za zhi Chinese journal of pathology. 2013; 42(3):147-52. doi: 10.3760/cma.j.issn.0529-5807.2013.03. 002 PMID: 23769431
44. Dias P, Chen B, Dilday B, Palmer H, Hosoi H, Singh S, et al. Strong immunostaining for myogenin in rhabdomyosarcoma is significantly associated with tumors of the alveolar subclass. The American journal of pathology. 2000; 156(2):399-408. PMID: 10666368
45. Fu D, Lv X, Hua G, He C, Dong J, Lele SM, et al. YAP regulates cell proliferation, migration, and steroidogenesis in adult granulosa cell tumors. Endocrine-related cancer. 2014; 21(2):297-310. doi: 10. 1530/ERC-13-0339 PMID: 24389730
46. Lau AN, Curtis SJ, Fillmore CM, Rowbotham SP, Mohseni M, Wagner DE, et al. Tumor-propagating cells and Yap/Taz activity contribute to lung tumor progression and metastasis. The EMBO journal. 2014; 33(5):468-81. doi: 10.1002/embj.201386082 PMID: 24497554
47. Zhou D, Conrad C, Xia F, Park JS, Payer B, Yin Y, et al. Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer cell. 2009; 16(5):425-38. doi: 10.1016/j.ccr.2009.09.026 PMID: 19878874
48. Hsu JH, Lawlor ER. BMI-1 suppresses contact inhibition and stabilizes YAP in Ewing sarcoma. Oncogene. 2011; 30(17):2077-85. doi: 10.1038/onc.2010.571 PMID: 21170084
49. Shao DD, Xue W, Krall EB, Bhutkar A, Piccioni F, Wang X, et al. KRAS and YAP1 converge to regulate EMT and tumor survival. Cell. 2014; 158(1):171-84. doi: 10.1016/j.cell.2014.06.004 PMID: 24954536
50. Kapoor A, Yao W, Ying H, Hua S, Liewen A, Wang Q, et al. Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. Cell. 2014; 158(1):185-97. doi: 10.1016/j.cell.2014.06.003 PMID: 24954535
51. Lin L, Sabnis AJ, Chan E, Olivas V, Cade L, Pazarentzos E, et al. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nature genetics. 2015; 47(3):250-6. doi: 10. 1038/ng.3218 PMID: 25665005
52. Yu FX, Zhang K, Guan KL. YAP as oncotarget in uveal melanoma. Oncoscience. 2014; 1(7):480-1. PMID: 25594048
53. Xie Q, Chen J, Feng H, Peng S, Adams U, Bai Y, et al. YAP/TEAD-mediated transcription controls cellular senescence. Cancer research. 2013; 73(12):3615-24. doi: 10.1158/0008-5472.CAN-12-3793 PMID: 23576552
54. Kipling D. Telomere structure and telomerase expression during mouse development and tumorigenesis. Eur J Cancer. 1997; 33(5):792-800. PMID: 9282119
55. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, et al. Specific association of human telomerase activity with immortal cells and cancer. Science. 1994; 266(5193):2011-5. PMID: 7605428
56. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer. 1997; 33 (5):787-91. PMID: 9282118